Pro forma year-finish cash now over $700 million At-the-Market Program has been terminated COLLEGE PARK, MD – (March 10, 2025)…
Read More
Assessing the Strategic Implications and Investor Appeal of At-the-Market Equity Offerings in Growth-Stage Biotech Firms
In the high-stakes world of growth-stage biotech, capital raising strategies often serve as a barometer for both financial health and…
Read More
